Why BioVie (BIVI) Stock Is Up Today

By: Quiver PriceTracker

Posted: 1 day, 13 hours ago / Aug. 12, 2026 3:39 p.m. UTC

BIVI

BioVie Inc. (BIVI) is up 66.9% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear same-day catalyst was not easy to confirm, so the move appears tied to renewed speculative interest in BioVie’s late-stage clinical story. This could be because traders are revisiting the company’s recent Parkinson’s disease update and its approaching long COVID data window, both of which can drive sharp swings in a low-priced biotech stock.

Details:

BioVie said in May that the last patient evaluation visit was completed for its Phase 2 SUNRISE-PD study of bezisterim in early-stage Parkinson’s disease, with topline results targeted for the third quarter of 2026.

The company also said in late May that its Phase 2 ADDRESS-LC study in long COVID reached full enrollment, and management pointed to topline data later in the summer of 2026.

BioVie describes itself as a clinical-stage company focused on neurological and neurodegenerative diseases, which means the stock can react strongly to shifting expectations around trial readouts rather than revenue or earnings.

With no widely visible fresh financing or earnings headline tied to today’s jump, the move may reflect momentum trading and repositioning around upcoming clinical milestones.

Sources:

BioVie Investor Relations, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIVI Hedge Fund Activity

We have seen 12 institutional investors add shares of $BIVI stock to their portfolio, and 15 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DRW SECURITIES, LLC removed 128,356 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $179,698
RENAISSANCE TECHNOLOGIES LLC added 39,900 shares (+142.4%) to their portfolio in Q1 2026, for an estimated $55,860
CITADEL ADVISORS LLC added 27,142 shares (+149.5%) to their portfolio in Q1 2026, for an estimated $37,998
PHILADELPHIA TRUST CO removed 25,000 shares (-33.3%) from their portfolio in Q2 2026, for an estimated $48,500
HRT FINANCIAL LP added 23,482 shares (+inf%) to their portfolio in Q1 2026, for an estimated $32,874
TWO SIGMA INVESTMENTS, LP removed 21,412 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $29,976
FMR LLC removed 16,294 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $22,811

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.